<?xml version='1.0' encoding='utf-8'?>
<document id="26350273"><sentence text="Effects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tablet."><entity charOffset="11-21" id="DDI-PubMed.26350273.s1.e0" text="paroxetine" /><entity charOffset="80-91" id="DDI-PubMed.26350273.s1.e1" text="hydrocodone" /><entity charOffset="166-177" id="DDI-PubMed.26350273.s1.e2" text="hydrocodone" /><pair ddi="false" e1="DDI-PubMed.26350273.s1.e0" e2="DDI-PubMed.26350273.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s1.e0" e2="DDI-PubMed.26350273.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s1.e0" e2="DDI-PubMed.26350273.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26350273.s1.e1" e2="DDI-PubMed.26350273.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s1.e1" e2="DDI-PubMed.26350273.s1.e2" /></sentence><sentence text="A single-entity, once-daily, extended-release formulation of hydrocodone bitartrate (HYD) has been developed for the management of moderate to severe chronic pain"><entity charOffset="61-83" id="DDI-PubMed.26350273.s2.e0" text="hydrocodone bitartrate" /><entity charOffset="85-88" id="DDI-PubMed.26350273.s2.e1" text="HYD" /><pair ddi="false" e1="DDI-PubMed.26350273.s2.e0" e2="DDI-PubMed.26350273.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s2.e0" e2="DDI-PubMed.26350273.s2.e1" /></sentence><sentence text=" Hydrocodone undergoes cytochrome P-450 (CYP)-mediated metabolism involving the CYP3A4 and CYP2D6 isozymes"><entity charOffset="1-12" id="DDI-PubMed.26350273.s3.e0" text="Hydrocodone" /></sentence><sentence text=" CYP3A4 yields norhydrocodone, a major inactive metabolite, whereas CYP2D6 yields hydromorphone, a minor active metabolite"><entity charOffset="15-29" id="DDI-PubMed.26350273.s4.e0" text="norhydrocodone" /><entity charOffset="82-95" id="DDI-PubMed.26350273.s4.e1" text="hydromorphone" /><pair ddi="false" e1="DDI-PubMed.26350273.s4.e0" e2="DDI-PubMed.26350273.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s4.e0" e2="DDI-PubMed.26350273.s4.e1" /></sentence><sentence text=" This study examined the influence of the coadministration of paroxetine, a strong selective CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone (and hydromorphone) in healthy adults"><entity charOffset="62-72" id="DDI-PubMed.26350273.s5.e0" text="paroxetine" /><entity charOffset="148-159" id="DDI-PubMed.26350273.s5.e1" text="hydrocodone" /><entity charOffset="165-178" id="DDI-PubMed.26350273.s5.e2" text="hydromorphone" /><pair ddi="false" e1="DDI-PubMed.26350273.s5.e0" e2="DDI-PubMed.26350273.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s5.e0" e2="DDI-PubMed.26350273.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s5.e0" e2="DDI-PubMed.26350273.s5.e2" /><pair ddi="false" e1="DDI-PubMed.26350273.s5.e1" e2="DDI-PubMed.26350273.s5.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s5.e1" e2="DDI-PubMed.26350273.s5.e2" /></sentence><sentence text="" /><sentence text="In this randomized, double-blind, 2-period, 2-treatment crossover study, 24 healthy subjects received paroxetine 20 mg or placebo once daily for 12 days and an HYD 20-mg tablet on day 10 of each period"><entity charOffset="102-112" id="DDI-PubMed.26350273.s7.e0" text="paroxetine" /><entity charOffset="160-169" id="DDI-PubMed.26350273.s7.e1" text="HYD" /><pair ddi="false" e1="DDI-PubMed.26350273.s7.e0" e2="DDI-PubMed.26350273.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s7.e0" e2="DDI-PubMed.26350273.s7.e1" /></sentence><sentence text="" /><sentence text="Hydrocodone mean Cmax and t½ and median Tmax values were similar with paroxetine or placebo coadministration (16"><entity charOffset="0-11" id="DDI-PubMed.26350273.s9.e0" text="Hydrocodone" /><entity charOffset="70-80" id="DDI-PubMed.26350273.s9.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.26350273.s9.e0" e2="DDI-PubMed.26350273.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s9.e0" e2="DDI-PubMed.26350273.s9.e1" /></sentence><sentence text="8 vs 15" /><sentence text="9 ng/mL, 8" /><sentence text="5 vs 8" /><sentence text="4 hours, and 18" /><sentence text="0 vs 18" /><sentence text="0 hours, respectively), as were mean AUC0-t and AUC0-∞ values (342" /><sentence text="9 vs 325" /><sentence text="3 ng · h/mL and 346" /><sentence text="3 vs 328" /><sentence text="5 ng · h/mL)" /><sentence text=" The 90% CIs of the geometric mean ratios of the hydrocodone AUC and Cmax values were fully within the predetermined range of 80% to 125%, suggesting that there was no effect of multiple doses of paroxetine on systemic exposure to hydrocodone"><entity charOffset="49-60" id="DDI-PubMed.26350273.s20.e0" text="hydrocodone" /><entity charOffset="196-206" id="DDI-PubMed.26350273.s20.e1" text="paroxetine" /><entity charOffset="231-242" id="DDI-PubMed.26350273.s20.e2" text="hydrocodone" /><pair ddi="false" e1="DDI-PubMed.26350273.s20.e0" e2="DDI-PubMed.26350273.s20.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s20.e0" e2="DDI-PubMed.26350273.s20.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s20.e0" e2="DDI-PubMed.26350273.s20.e2" /><pair ddi="false" e1="DDI-PubMed.26350273.s20.e1" e2="DDI-PubMed.26350273.s20.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s20.e1" e2="DDI-PubMed.26350273.s20.e2" /></sentence><sentence text=" Mean hydromorphone AUC0-t and Cmax values were decreased with paroxetine versus placebo (0"><entity charOffset="6-19" id="DDI-PubMed.26350273.s21.e0" text="hydromorphone" /><entity charOffset="63-73" id="DDI-PubMed.26350273.s21.e1" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.26350273.s21.e0" e2="DDI-PubMed.26350273.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s21.e0" e2="DDI-PubMed.26350273.s21.e1" /></sentence><sentence text="64 vs 3" /><sentence text="8 ng · h/mL and 0" /><sentence text="06 vs 0" /><sentence text="19 ng/mL), whereas Tmax values remained similar (18" /><sentence text="0 vs 16" /><sentence text="1 hours, respectively)" /><sentence text=" The mean hydromorphone AUC0-∞ value could not be calculated"><entity charOffset="10-23" id="DDI-PubMed.26350273.s28.e0" text="hydromorphone" /></sentence><sentence text=" Both regimens were well tolerated; after HYD administration, the numbers of adverse events were similar between the 2 treatment regimens, and all adverse events were mild"><entity charOffset="42-54" id="DDI-PubMed.26350273.s29.e0" text="HYD" /></sentence><sentence text="" /><sentence text="In this study, the coadministration of single-dose HYD with paroxetine at steady state did not alter systemic exposure to hydrocodone, suggesting that HYD can be coadministered with CYP2D6 inhibitors at therapeutic doses, without dosage modification"><entity charOffset="60-70" id="DDI-PubMed.26350273.s31.e0" text="paroxetine" /><entity charOffset="122-133" id="DDI-PubMed.26350273.s31.e1" text="hydrocodone" /><entity charOffset="51-61" id="DDI-PubMed.26350273.s31.e2" text="HYD" /><entity charOffset="151-161" id="DDI-PubMed.26350273.s31.e3" text="HYD" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e2" e2="DDI-PubMed.26350273.s31.e2" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e2" e2="DDI-PubMed.26350273.s31.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e2" e2="DDI-PubMed.26350273.s31.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e2" e2="DDI-PubMed.26350273.s31.e3" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e0" e2="DDI-PubMed.26350273.s31.e0" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e0" e2="DDI-PubMed.26350273.s31.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e0" e2="DDI-PubMed.26350273.s31.e3" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e1" e2="DDI-PubMed.26350273.s31.e1" /><pair ddi="false" e1="DDI-PubMed.26350273.s31.e1" e2="DDI-PubMed.26350273.s31.e3" /></sentence><sentence text="" /></document>